Bank of Montreal Can boosted its stake in shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) by 2.9% during the third quarter, Holdings Channel reports. The institutional investor owned 26,018 shares of the biopharmaceutical company’s stock after buying an additional 733 shares during the period. Bank of Montreal Can owned approximately 0.06% of Sucampo Pharmaceuticals worth $320,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Boston Partners increased its position in Sucampo Pharmaceuticals by 36.6% in the second quarter. Boston Partners now owns 238,519 shares of the biopharmaceutical company’s stock valued at $2,617,000 after buying an additional 63,965 shares in the last quarter. Princeton Alpha Management LP bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth about $138,000. SG Americas Securities LLC bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth about $442,000. Emerald Acquisition Ltd. bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth about $1,075,000. Finally, Societe Generale bought a new position in shares of Sucampo Pharmaceuticals during the second quarter worth about $442,000. Hedge funds and other institutional investors own 40.34% of the company’s stock.
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) traded up 0.96% during midday trading on Friday, reaching $15.85. The company had a trading volume of 484,015 shares. The company has a 50-day moving average price of $13.39 and a 200-day moving average price of $12.09. Sucampo Pharmaceuticals Inc. has a one year low of $9.59 and a one year high of $18.75. The stock has a market capitalization of $678.67 million, a price-to-earnings ratio of 53.55 and a beta of 1.62.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.02. Sucampo Pharmaceuticals had a return on equity of 44.19% and a net margin of 6.29%. The business earned $57.90 million during the quarter, compared to analysts’ expectations of $51.30 million. During the same period in the previous year, the business earned $0.16 earnings per share. The firm’s revenue was up 73.4% on a year-over-year basis. On average, equities analysts expect that Sucampo Pharmaceuticals Inc. will post $1.22 earnings per share for the current year.
SCMP has been the subject of a number of analyst reports. Maxim Group lowered their price objective on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, August 1st. Vetr downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price objective for the company. in a research report on Monday, September 19th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Jefferies Group lowered their price objective on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating for the company in a research report on Thursday, August 4th. Finally, Mizuho raised their price objective on Sucampo Pharmaceuticals from $13.00 to $16.00 and gave the stock a “neutral” rating in a research report on Monday, November 14th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Sucampo Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $17.33.
In other news, CFO Andrew P. Smith sold 1,766 shares of the company’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $15.58, for a total value of $27,514.28. Following the completion of the transaction, the chief financial officer now directly owns 348 shares in the company, valued at approximately $5,421.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.31% of the stock is owned by insiders.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.